The Global Drug sales of Keytruda stood at USD 20,937 Millions in 2022
The indicator recorded a historical growth (CAGR) of24% between 2019 to 2022 and is expected to grow by ...
GlobalData projects the indicator to grow at a CAGR of...
Pembrolizumab (Keytruda) is an antineoplastic immunomodulating agent. Keytruda is formulated as lyophilised powder for solution, solution concentrate for intravenous route of administration.
Mechanism of Action
Pembrolizumab (Keytruda) acts as PD-1 blockade agent. Binding of the PD-1 ligands, PD-L1 and PD-L2, to the PD-1 receptor found on T cells, inhibits T cell proliferation and cytokine production. Upregulation of PD-1 ligands occur in some tumors and signaling through this pathway can contribute to inhibition of active T-cell immune surveillance of tumors. Pembrolizumab is a monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response.
Keytruda Overview
Keytruda is marketed for the treatment of several indications in Infectious Disease, Non-Malignant Disorders, Oncology, and Women's Health therapy areas.
Keytruda is indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. Keytruda as monotherapy is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults. Some of the other indications Keytruda is marketed for includes Esophageal Squamous Cell Carcinoma (ESCC), Bile Duct Cancer (Cholangiocarcinoma), Renal Cell Carcinoma, Non-Small Cell Lung Cancer, Squamous Cell Carcinoma, Esophageal Cancer, Adenocarcinoma of The Gastroesophageal Junction, Cervical Cancer, Melanoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Head and Neck Cancer, Gastric Cancer, Bladder Cancer, Small-Cell Lung Cancer, Solid Tumor, and Endometrial Cancer.
Keytruda was first approved in 2014 and is sold globally including the US, the UK, France, Germany, and Japan by Merck & Co Inc and its subsidiaries. Keytruda drug sales recorded a low-double digit Year on Year growth in 2022. Keytruda drug sales include the historical sales that are derived from company financial reports, and consensus forecasts are calculated based on company-specific broker reports as well as GlobalData’s proprietary methodology.
United States of America
China
Switzerland
United States of America
United States of America
United States of America
United States of America
Germany
France
Switzerland
Don’t wait - discover a universe of connected data & insights with your next search. Browse over 28M data points across 22 industries.
Access more premium companies when you subscribe to Explorer